SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Aviron
AVIR 3.260+0.3%Nov 7 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mauser96 who wrote (345)9/2/1998 4:01:00 PM
From: Arthur Radley  Read Replies (1) of 645
 
It is my understanding that the drug is currently manufactured in Europe for AVIR. Since the delivery will be oral and go directly to the lungs, it is very important for the purity of the drug. Considering the major users of this drug will be young children and the elderly, side-effects from any impurity of the drug would offer major liability to AVIR.
On the negative side, AVIR should have paid more attention to this issue before approaching the FDA. It appears this is only a delay, but one year is a long long time.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News